In The Holiday Shortened Easter Week, These Large-Cap Stock Were Top Performers (Apr 14-Apr 18): Are These In Your Portfolio?
Notable Healthcare Headlines for the Week: UnitedHealth, Eli Lilly, J&J in Focus
Eli Lilly Plans US Production of Latest Weight-loss Pill
Trending Stocks as Wall Street Wrestles With Market Volatility Amid Tariff Tensions
Wall Street Trims Ratings for Novo Nordisk Stock, as Ozempic's Competition Grows -- Barrons.com
10 Health Care Stocks Whale Activity In Today's Session
Eli Lilly (NYSE:LLY) Advances Diabetes Treatment And Partners With BigHat On Antibody Discovery
Catalyst Watch: Spotlight on Tesla, Alphabet Earnings, AACR Drug Data, and Global PMI Reports
Eli Lilly Vows to Make Weight-Loss Pill in U.S. as Trump Pushes for Domestic Manufacturing -- Barrons.com
Eli Lilly and Company (LLY): One of the Best Long Term Stocks to Buy According to Billionaires
Daily short sale tracking: Petroleo Brasileiro SA Petrobras's short volume increased by 3 million, with a short sale ratio of 21%
Today's Analyst Rating | Evercore Upgrades Apple to Buy, Morgan Stanley Cuts Its Price Target Cut on Alphabet-C to $185
US MOVERS&SHAKERS Apr 14-Apr 18, 2025
The "miracle weight loss drug" has entered the oral era. Will Eli Lilly and Co become the king of weight loss medications?
Wall Street Analysts generally believe that the GLP-1 weight loss medication field is transitioning from injectable forms to more convenient oral forms, and Eli Lilly and Co has already gained an early lead. This fierce, multi-year competition has clearly shown a winner; at least for now, Eli Lilly and Co has been crowned by the market as the new king in the realm of GLP-1 drugs.
Chugai Highlights Eli Lilly's Promising Phase 3 Results for Orforglipron
J.P. Morgan Maintains Eli Lilly and Co(LLY.US) With Buy Rating
Leerink Partners Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Raises Target Price to $989
BMO Capital Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Cuts Target Price to $900
Top Gap Ups and Downs on Thursday: LLY, UNH, NVO and More
Eli Lilly and Co Options Spot-On: On April 17th, 167.71K Contracts Were Traded, With 285.38K Open Interest